Adil Duran

This inventor holds 15 USPTO granted patents and 3 published patent applications, plus 2 CIPO patents and 6 EPO patents. Top assignees: Boehringer Ingelheim International Gmbh, Ajinomoto Co., Ltd.. Active years: 2007-2017.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Adil Duran. Retrieved from https://idiyas.com/inventor/adil-duran

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 15 (Patent Applications = 3)

% Patents Active = 73.3

CIPO Patents = 2

EPO Patents = 6 (Patent Applications = 9)

Average Co-Inventor Count = 3.4

ph-index = 6

Forward Citations = 176(Granted Patents)

Location History:

Rissegg, DE (2007 - 2013)
Biberach, DE (2009 - 2013)
Rigefield, CT (US) (2013)
Biberach an der Riss, DE (2012 - 2017)

Company Filing History:

14 out of 1,562

Boehringer Ingelheim International Gmbh

where one patent can have more than one assignee

Years Active: 2007-2017

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9751855 - Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines (2017-09-05),

2. 9499546 - Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines (2016-11-22),

3. 8883805 - Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines (2014-11-11),

4. 8680280 - Process for the manufacturing of CRR inhibitors (2014-03-25),

5. 8420809 - Process for the manufacturing of betamimetics (2013-04-16),

6. 8394791 - Crystalline, enantiomerically pure salt form of a beta-agonist, and the use thereof as a drug (2013-03-12),

7. 8372974 - Regioselective preparation of substituted pyrimidines (2013-02-12),

8. 8334383 - Regioselective preparation of substituted pyrimidines (2012-12-18),

9. 8207335 - Process for making certain compounds having B1 antagonistic activity (2012-06-26),

10. RE43115 - Process for the manufacture of fused piperazin-2-one derivatives (2012-01-16),

11. 7838500 - Crystalline form of 1'-(1-methylethyl)-4′-[(2-fluoro-4-methoxyphenyl)methyl]-5′-methyl-1H-pyrazol-3′-O-β-D-glucopyranoside, a method for its preparation and the use thereof for preparing medicaments (2010-11-23),

12. 7820815 - Process for the preparation of chiral 8-(-3-aminopiperidin-1-yl) xanthines (2010-10-26),

13. 7626019 - Intermediate compounds for the manufacture of fused piperazin-2-one derivatives (2009-12-01),

14. 7524822 - Crystalline form of 1'-(1-methylethyl)-4′-[(2-fluoro-4-methoxyphenyl)methyl]-5′-methyl-1H-pyrazol-3′-O-β-D-glucopyranoside, a method for its preparation and the use thereof for preparing medicaments (2009-04-28),

15. 7238807 - Process for the manufacture of fused piperazin-2-one derivatives (2007-07-03),

Title: Adil Duran: Innovator in Chiral Chemistry

Introduction

Adil Duran is a prominent inventor based in Biberach, Germany. He has made significant contributions to the field of chiral chemistry, holding a total of 15 patents. His work focuses on the preparation of enantiomerically pure compounds, which are crucial in various pharmaceutical applications.

Latest Patents

Among his latest innovations is a patent for the "Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines." This invention relates to an improved method for synthesizing enantiomerically pure 8-(3-aminopiperidin-1-yl)-xanthines, showcasing his expertise in developing efficient chemical processes.

Career Highlights

Adil Duran has worked with notable companies in the pharmaceutical industry, including Boehringer Ingelheim International GmbH and Ajinomoto Co., Ltd. His experience in these organizations has allowed him to refine his skills and contribute to groundbreaking research in chiral compounds.

Collaborations

Throughout his career, Duran has collaborated with esteemed colleagues such as Waldemar F. Pfrengle and Thorsten Pachur. These partnerships have further enhanced his research and development efforts in the field.

Conclusion

Adil Duran's innovative work in chiral chemistry and his impressive portfolio of patents highlight his significant impact on the pharmaceutical industry. His contributions continue to advance the field and improve the synthesis of important compounds.

Profile summary based on public USPTO records.